Oxnard et al. demonstrated via proof-of-principle the utility of ddPCR to perform minimally invasive genotyping of plasma ctDNA samples from patients with KRAS-mutant and EGFR-mutant NSCLC, showcasing the high sensitivity and specificity of this technology [71]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.